valu usd unless otherwis note
rais continu given
view manag set conserv guidanc keep
mind gener competit zytiga remicad brand
price dynam howev key brand three segment push
organ revenu growth guidanc trade
ep estim share offer attract valu long-term
investor despit headlin risk associ talc litig
guidanc organ revenu growth reason
start point forecast absorb bp gener eros mainli
remicad zytiga believ consum medic devic
grow least well base
perform five mega blockbust
growth brand tremfya erleada opsumit uptravi
forecast ww revenu rang includ
currenc headwind net neg impact
divestitur lifescan advanc surgic product non-gaap ep
guidanc includ fx headwind
demand key brand stronger intern
simponi aria invega sustenna/trinza grow faster
outsid zytiga grew intern tremfya
earli launch recent receiv approv erleada
europ therefor high-single-digit cc growth aggress
intern pharmaceut segment opinion
suffici drive ww pharma growth
estim growth
yield ww pharma growth
medic devic consum see benefit new product
organ growth improv consist manag
commentari may busi review intervent solut
vision continu deliv in-lin better result orthoped
start better knee spine sale show sign
stabil consum new product oral babi
supplement strong perform beauti over-the-counter overal
improv trend orthoped babi oral give us
confid segment deliv organ growth
chang estim price target revis ww revenue/ep
estim currenc
xarelto bigger discount zytiga faster gener eros
main reason lower estim estim impli
revenu growth ep growth par correspond
report figur estim chang reduc price target
old believ impli price-to-earnings jnj
averag move higher busi repeat
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part sotp price-to-earnings analysi valu three segment
medic devic consum separ
base peer group multipl base case estim
assum mid-single-digit oper growth
exclud zytiga margin expans share buyback
price target impli price-to-earnings multipl
ep estim y/i
 lift revenu growth basi point
restructur portfolio ration lead
superior oper leverag rel base case scenario
pharmaceut price rhetor lead legisl
chang govern negoti price
multipl ep estim y/
assumpt
aggress eros remicad zytiga
brand biosimilar gener competit lack
 depress revenu growth neg
downward pressur multipl downsid
scenario impli price-to-earnings multipl y/i
ep estim assumpt
forecast ww organ revenu growth
forecast take account signific sale eros
zytiga besid biosimilar competit remicad
gener eros brand base prescript
trend key brand improv observ
medic devic consum believ
scope upward revis guidanc
mega-blockbust
contribut new product main growth driver
segment mega-blockbust brand
ww annual peak sale potenti billion
stelara imbruvica darzalex xarelto invega
sustenna/trinza estim ww sale
mega-blockbust increas high-teen led
stelara imbruvica darzalex new brand tremfya
erleada contribut billion sale
pharmaceut pipelin enough late-stag compound
produc steadi flow new drug nme
esketamin erdafitinib submit approv
year market esketamin
studi treatment-resist depress
major depress disord patient risk suicid
ideat erdafitinib expand jnj oncolog portfolio solid
set goal grow market medic
devic end-market annual growth
rate around certain end-market vision
electrophysiolog advanc surgeri grow
line market compens slower-growth
orthoped categori new product launch year
qualiti improv adapt
busi model chang environ
element strategi achiev goal
vision clear strategi extend leadership
contact lens forecast segment within vision
contact lens surgic grow compound-annual-growth-rate
plan launch two new product year
contact lens among first
transit contact lens expect launch next year
integr abbott medic optic span countri
complet disrupt custom
exhibit revenu estim report result
exhibit intern pharmaceut revenu estim report result
exhibit pharmaceut ww revenu organ growth rate therapeut
categori geographi
sale ww ww pharma excl ww ww pharma excl ww ww pharma excl ww ww pharma excl diseas ww ww pharma excl ww ww pharma ww excl growth medic suppli devic
exhibit medic devic estim report result ww revenu
exhibit ww revenu organ growth rate variou categori within devic
geographi
medcial devic segment ww includ fxy/i y/i product ww ww devic excl ww ww devic excl ww ww devic excl ww ww devic ww excl growth medic suppli devic
exhibit consum estim report result ww revenu
exhibit ww revenu organ growth rate variou categori within consum
geographi
consum segment ww includ fxmedcial devic segment ww includ fxy/i y/i product ww ww consum excl ww ww consum excl ww ww consum excl ww ww consum excl ww ww consum excl ww consum excl ww excl growth medic suppli devic
exhibit revenu model
geographi wwww revenu brand growth ww excl revenu medic suppli devic
segmentsp/ estimate ep contributioncontribut price targetconsum million except ep targetupsid scenariodownsidetot interest expens share dilut medic suppli devic
exhibit estim vs report result
price target base sum-of-the-part sotp analysi target price-to-earnings
multipl base year medic devic consum segment
respect correspond peer group multipl
assign slight premium multipl segment
superior underli growth outlook rel market growth estim year period
pharmaceut segment contribut toward price target medic devic
consum price target impli blend price-to-earnings multipl ep estim
y/i discount price-to-earnings ntm averag price target support
outperform rate share
risk rate price target
face risk typic global diversifi healthcar compani includ
slump navig fda may risk price target rate
johnson johnson one largest diversifi healthcar busi
world oper compani encompass broad rang product across
healthcar field compani world-wide busi divid three main segment
medic devic diagnost sale consum
